The frequency of progression of atrophic gastritis and/or intestinal metaplasia among all 69 participants assessed at baseline was 14%; this frequency was relatively high in participants who did not complete treatment to eliminate Hp before follow-up, did not test negative for Hp before follow-up and/or had moderate or marked Hp density at follow-up. The gene discussed is HP; the disease is chronic atrophic gastritis.